key: cord-0837723-dskxzeyi
authors: Pratama, N. R.; Wafa, I. A.; Budi, D. S.; Sutanto, H.; Asmarawati, T. P.; Wungu, C. D. K.
title: Effectiveness of Covid-19 vaccines against SARS-CoV-2 Omicron variant (B.1.1.529): A systematic review with meta-analysis and meta-regression
date: 2022-05-02
journal: nan
DOI: 10.1101/2022.04.29.22274454
sha: cf280e815a4e0ded85ce4572ec89c290cb1e5911
doc_id: 837723
cord_uid: dskxzeyi

Background: There is a need for evaluation regarding vaccine effectiveness (VE) and the urgency of booster vaccination against Covid-19 B.1.1.529 (Omicron) variant. Methods: Systematic search was conducted on April 6th, 2022, on databases (PubMed, ScienceDirect, CENTRAL, Web of Science, Scopus). VE difference (VED) estimates were assessed using random-effects model and DerSimonian-Laird tau estimators. Two models result, i.e., within 3 months and within 3 months or more, are compared. VE versus time meta-regression analysis was evaluated using mixed-effects model with Restricted-Maximum Likelihood tau estimators and Hartung-Knapp adjustments. Results: Ad26.COV2.S, BNT162b2, ChAdOx1 nCov-19, and mRNA-1273 vaccines were included in the analyses. Compared to full dose, booster dose of overall vaccines provided better protection against any (VED=22% (95%CI 15%-29%), p<0.001), severe (VED=20% (95%CI 8%-32%), p=0.001) and symptomatic (VED=22% (95%CI 11%-34%), p<0.001) Omicron infections within 3 months, as well as within 3 months or more (VED=30% (95%CI 24%-37%), p<0.001 for any, VED=18% (95%CI 13%-23%), p<0.001 for severe and VED=37% (95%CI 29%-46%), p<0.001 for symptomatic infections). The meta-regression analysis of overall vaccines revealed that the full dose VE against any and symptomatic Omicron infections were significantly reduced each month by 3.0% (95%CI 0.9%-4.8%, p=0.004) and 5.2% (95%CI 3.3%-7.1%, p=0.006), respectively; whereas booster dose effectiveness against severe and symptomatic Omicron infections were decreased by 3.7% (95%CI 5.1%-12.6%, p=0.030) and 3.9% (95%CI 1.2%-6.5%, p=0.006), respectively. Conclusion: Compared to full dose only, a booster dose addition provides better protection against B.1.1.529 infection. Although the VE estimates of Ad26.COV2.S, BNT162b2, ChAdOx1 nCov-19, and mRNA-1273 vaccines against B.1.1.529 infection after both full and booster doses are generally moderate, and the booster dose provides excellent protection against severe infection, it is important to note that the VE estimates decline over time, suggesting the need for a regular Covid-19 booster injection after certain period of time to maintain VE.

reduction in VE against the Omicron variant as compared to the earlier variants [14] [15] [16] , potentially 23 affecting the current Covid-19 vaccination strategy. Therefore, with the surge of new SARS- 24 CoV-2 variants, booster vaccine doses were administered to confer stronger immunity, which 25 hopefully could increase VE. 17, 18 However, due to global disparity in the availability, 26 distribution of COVID-19 vaccines and the vaccination rates, developing countries were 27 pushed to expedite booster vaccination with (limited) available resources to foster their booster 28 vaccination rates. 19,20 29 Since an equal distribution of booster vaccines remains a challenge and Omicron's 30 spike antigen landscape is heavily altered, there is a need for explorations regarding the 31 effectivity of currently available vaccines and the urgency of booster vaccination against 32 SARS-CoV-2 Omicron variant. Here, we performed systematic review and meta-analysis to 33 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 2, 2022. ; https://doi.org/10.1101/2022.04.29.22274454 doi: medRxiv preprint From databases and manual search, 1,278 and 786 records were retrieved, respectively. A total 91 of 147 duplicates were subsequently removed. Following the screening of titles and abstracts, 92 60 potential articles were selected for review. After a full-text review, 21 observational studies, 93 consisting of 5 cohorts and 16 test-negative case-control studies, were included in the 94 systematic review, meta-analysis, and meta-regression. The overall screening process of this 95 systematic review and meta-analysis is summarized in the PRISMA flow diagram (Figure 1) . 96 The quality assessment of each study using the NOS critical appraisal checklist is listed in 97 Table S2 and S3. All included studies were considered good-quality studies according to the 98 quality assessment.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Reports sought for retrieval (n = 17)

Reports not retrieved (n = 0)

Reports assessed for eligibility (n = 17)

Reports excluded due to: -Insufficient information (n = 4)

Records identified from: MedRxiv (n = 455) bioRxiv (n = 312) Bibliographic search (n = 19) Reports assessed for eligibility (n = 43)

Reports excluded due to: -Does not address research question (n = 21) -Insufficient information (n = 14)

Studies included in review (n = 21) Reports of included studies (n = 21)

Reports sought for retrieval (n = 43)

Reports not retrieved (n = 0) 

^T est-negative case-control study design.

109 § 1-OR is 1-(odds among vaccinated group)/(odds among unvaccinated group); 1-RR is 1-(risk among vaccinated group)/(risk among unvaccinated group); 1-HR is (1-RR)x100%, or (1-HR)x100% (Table 1) . The VE from each study with its 95% clinical 134 interval (CI) for full and booster doses are summarized in Table S4 and 135 infection. For VED between the full and booster doses, we analyzed the results using 2 models:

146 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 2, 2022. ; https://doi.org/10.1101/2022.04.29.22274454 doi: medRxiv preprint the 'within 3 months' and the 'within 3 months or more' models. The 'within 3 months' model 147 included data in the first 3 months reported by each study and the 'within 3 months or more' 148 model included data in the first 3 months or more reported by each study. A . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In the 'within 3 months' model, the pooled results for preventing any, severe and 166 symptomatic infections showed that booster dose had a significantly higher VE than that of the 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 2, 2022. ; https://doi.org/10.1101/2022.04.29.22274454 doi: medRxiv preprint full dose (VED of 22% (95%CI 15% to 29%), 20% (95%CI 8% to 32%), and 22% (95%CI 168 11% to 34%), respectively). In the 'within 3 months or more' model, the pooled results also 169 showed a better VE on booster dose for any, severe and symptomatic infections (VED of 30% 170 (95%CI 24% to 37%), 18% (95%CI 13% to 23%), and 37% (95%CI 29% to 46%), 171 respectively).

The heterogeneity of overall and subgroup analyses is summarized in Table S15 and   173   Table S16 . Leave-one-out sensitivity analyses performed on the overall analysis yielded 174 similar results in terms of effect estimates or statistical heterogeneity if each study was omitted 175 from the pooled results calculation (Figure S1-S6 to 24%) and 25% (95%CI 4% to 47%), respectively. These results were statistically significant 183 except that of the Mixture subgroup.

For severe infection, cohort and case-control subgroups showed significant results 185 (VEDs of 34% (95%CI 16% to 52%) and 13% (95%CI 5% to 20%), respectively). A further 186 subgroup analysis showed that the VED of BNT162b2, Mixture, and Mixture of mRNA 187 vaccines were 22% (95%CI 9% to 35%), 42% (95CI 32% to 52%), and 12% (95%CI 3% to 188 21%), respectively. All of these results were also statistically significant.

For symptomatic infection, cohort and case-control subgroups also showed VEDs of 190 51% (95%CI 49% to 53%) and 17% (95%CI 12% to 22%), respectively. In the BNT162b2, 191 ChAdOx1 nCov-19, and Mixture of mRNA vaccines subgroups, the booster dose had a better 192 VE than that of the full dose (VED of 25% (95%CI 5% to 46%, 16% (95%CI 2% to 30%), and 193 17% (95%CI 1% to 33%), respectively). These results were statistically significant, except for 194 the mRNA-1273 vaccine subgroup, the result did not reach statistical significance (VED of 195 23% (95%CI -7% to 54%)).

CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 2, 2022. 11% (95%CI 3% to 18%), respectively. All these results were statistically significant, except 209 that of mRNA-1273 subgroup with the VED of 15% (95%CI -24% to 54%).

For symptomatic infection, cohort and case-control subgroups also showed significant 211 results with VEDs of 51% (95%CI 49% to 53%) and 34% (95%CI 25% to 44%), respectively.

In the BNT162b2, ChAdOx1 nCov-19, mixture of mRNA vaccines, and mRNA-1273 213 subgroups, the booster dose also presented a better VE than that of the full dose (VEDs of 40% 214 (95%CI 26% to 55%), 27% (95%CI 14% to 41%), 28% (95%CI 20% to 36%), and 41% 215 (95%CI 25% to 56%), respectively). All of these results were statistically significant.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 2, 2022. ; https://doi.org/10.1101/2022.04.29.22274454 doi: medRxiv preprint 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 2, 2022. ; https://doi.org/10.1101/2022.04.29.22274454 doi: medRxiv preprint For the full dose vaccination, our meta-regression model estimated that the VE of full 234 dose against any and symptomatic infections were decreased in each month approximately by 235 3.0% (95%CI 0.9% to 4.8%) and 5.2% (95%CI 3.3% to 7.1%), respectively. Meanwhile, the 236 VE of booster dose against severe and symptomatic infections were decreased in each month 237 by 3.7% (95%CI 5.1% to 12.6%) and 3.9% (95%CI 1.2% to 6.5%), respectively. The detailed 238 results displaying the correlation of VE with time for each vaccine were presented in Table 2 .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 2, 2022. Vaccination or natural infection induces some immune cell subsets to turn into memory 274 cells through clonal expansions. 45 These previously primed cells could deliver a more robust 275 immune response in the secondary response, which is protective against severe disease.

Meanwhile, neutralizing antibodies can provide sterilizing immunity to prevent infection. 45-47 277 Neutralizing antibodies produced by plasma B cells decay over time, but long-lived plasma B is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 2, 2022. ; https://doi.org/10.1101/2022.04.29.22274454 doi: medRxiv preprint maturation process. 49, 50 Consequently, compared to full vaccination doses, an additional 282 booster vaccination dose would elicit a stronger immune response, 51 as evidenced by some 283 studies that reported a higher binding affinity and titers of neutralizing antibodies among 284 individuals who received three vaccination doses than that of two doses. [51] [52] [53] For instance, with 285 regard to the Omicron variant, the antibody titer induced by a booster dose of BNT162b2 at 1 286 month were 23-fold higher than that of full dose recipients. 54 287 Some studies showed that neutralizing antibody titers in Covid-19 were predictive of 288 immune protection. 55, 56 Neutralization titers continuously declined and appeared to be short-289 lived, 57, 58 and immune escape was observed in several SARS-CoV-2 variants of concern, 59-62 290 leading to reduced VE to some extent. 57 The immune escape may cause a reduced VE among 291 variants of concern, regardless of how long the last vaccination is given before the infection. A Our analyses showed a moderate VE reduction against the Omicron variant.

Nonetheless, the Omicron variant did not display an increased severity despite the increased 307 transmissibility. [69] [70] [71] Our results showed that VE estimates against severe infection still exhibit 308 a high efficacy for both the full and booster doses. However, we should be aware that new 309 variants of concern may emerge anytime, and always need to be anticipated. Maintaining the 310 Covid-19 pandemic to a low endemic level is seemingly a reasonable target before the 311 eradication of Covid-19 could be achieved. 312 We acknowledge that this study has some limitations. First, most results had high 313 heterogeneity. In the meta-analysis of VED outcome, we attempted to perform subgroup 314 analyses based on the study design and types of the vaccine, but the heterogeneity remained 315 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 2, 2022. In observational studies, some confounding factors are difficult to measure, thereby cannot be 319 controlled. For example, significant differences in the follow-up time would result in different 320 exposure received between the two groups. Moreover, the fact that VE declines over time 321 should be considered because cumulative comparison would lead to a bias. As the result, we 322 attempted to limit the time interval in one model to only include data within three months to 323 minimize this bias. Third, some included studies were obtained from preprint servers, which 324 had not been preceded by a peer-review process and the presented data may differ from the emergence of other variants of concern should always be anticipated. Nevertheless, these meta-334 analyses and meta-regression were constructed upon observational studies, in which several 335 confounders adjustment could be difficult to perform. Therefore, future RCTs might be able to 336 address several limitations of this study. Declaration of interests 344 The authors have declared no competing interest.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 2, 2022. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted May 2, 2022. ; https://doi.org/10.1101/2022.04.29.22274454 doi: medRxiv preprint

Science Brief: Omicron (B.1.1.529) Variant | CDC

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273

Booster Vaccination

Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines

Genetic Variants of SARS-CoV-2 -What Do They Mean?

Challenges in creating herd immunity to SARS-CoV-2 infection by mass vaccination

Herd Immunity: Understanding COVID-19

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. The Lancet Infectious Diseases

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2

SARS-CoV-2 variant Omicron: currently the most complete "escapee" from neutralization by antibodies and vaccines

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two singlecentre, double-blind, randomised, placebo-controlled phase 2 clinical trials

Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines

Global COVID-19 Vaccinations

The PRISMA 2020 statement: An updated guideline for reporting systematic reviews

The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses

Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes

Vaccine effectiveness against hospital admission in South African health care workers who received a homologous booster of Ad26.COV2 during an Omicron COVID19 wave: Preliminary Results of the Sisonke 2 Study

Association between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants

Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern

Duration of protection of BNT162b2 and mRNA-1273 COVID-19 vaccines against symptomatic SARS-CoV-2 Omicron infection in Qatar

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance -VISION Network, 10 States

Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years -VISION Network

Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha SARS-CoV-2 Variants in the United States: A Prospective Observational Study

Vaccine Dose Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults -VISION

BNT162b2 (Pfizer-Biontech) mRNA COVID-19 Vaccine Against Omicron-Related Hospital and Emergency Department Admission in a Large US Health System: A Test-Negative Design

Effectiveness of mRNA Vaccination in Preventing COVID-19 -Associated Invasive Mechanical Ventilation and Death -United States

Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance -VISION Network, 10 States

Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants

Effectiveness of mRNA COVID-19 Booster Vaccines against Omicron and Delta Variants among US Veterans

Effectiveness of BNT162b2 ( Pfizer-BioNTech ) mRNA Vaccination Against Multisystem Inflammatory Syndrome in Children Among Persons Aged 12 -18 Years -United States

Effectiveness of BNT162b2 and mRNA-1273 COVID-19 boosters against SARS-CoV-2 Omicron (B.1.1.529) infection in Qatar

Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study

The Effectiveness of mRNA Vaccine Boosters for Laboratory-Confirmed COVID-19 During a Period of Predominance of the Omicron Variant of SARS-CoV-2

Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2. medRxiv

Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5-11 Years and Adolescents Aged 12-15 Years -PROTECT Cohort

A meta-analysis of Early Results to predict Vaccine efficacy against Omicron

Immunological memory cells

Cancer Vaccines

Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative

Remembrance of Things Past: Long-Term B Cell Memory After Infection and Vaccination

The extent of affinity maturation differs between the memory and antibody-forming cell compartments in the primary immune response

Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial

Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis

Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study

Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccineelicited human sera

Evidence for antibody as a protective correlate for COVID-19 vaccines

Correlates of Vaccine-Induced Protection against SARS-CoV-2 Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD)

Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

SARS-CoV-2 variants, spike mutations and immune escape

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion

Parallel profiling of antigenicity alteration and immune escape of SARS-CoV-2 Omicron and other variants

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

SARS-CoV-2 T cell immunity: Specificity, function, durability, and role in protection

Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

Publisher Correction: A guide to vaccinology: from basic principles to new developments

Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome

Omicron variant (B.1.1.529) of SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance

Trends in Disease Severity and Health Care Utilization During the Early Omicron Variant Period Compared with Previous SARS-CoV-2 High Transmission Periods -United States

SARS-CoV-2 B.1.1.529 (Omicron) Variant Transmission Within Households -Four